Nuclear Cardiology: Present and Future

Current Problems in Cardiology

Volumn 31, Issue 9, 2006, Pages 557-629

  Russell III, Raymond R ^a   Zaret, Barry L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 125; ADENOSINE; ADENOSINE A2A RECEPTOR AGONIST; ALDOSE REDUCTASE INHIBITOR; AMMONIA N 13; ANTHRACYCLINE; ARBUTAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPYRIDAMOLE; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; RANOLAZINE; RUBIDIUM 82; RUBIDIUM CHLORIDE RB 81; TETROFOSMIN TC 99M; THALLIUM 201; THALLIUM CHLORIDE TL 201; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN; WATER O 15;

ANGINA PECTORIS; ANGIOGENESIS; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CARDIOVASCULAR SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOLOGY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ETHNIC GROUP; FATTY ACID METABOLISM; GATED IMAGING; GENE THERAPY; HEART DISEASE; HEART FAILURE; HEART INNERVATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART PERFUSION; HEART SCINTISCANNING; HUMAN; IMAGING SYSTEM; KIDNEY DISEASE; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR CARDIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RACE DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; SYMPATHETIC INNERVATION;

ANIMALS; APOPTOSIS; CARDIOLOGY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; GENE THERAPY; HUMANS; MYOCARDIAL REPERFUSION; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STEM CELL TRANSPLANTATION; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33747787311     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2006.05.002     Document Type: Article

References (376)

1. Zaret B.L., Strauss H.W., Martin N.D., et al. Noninvasive regional myocardial perfusion with radioactive potassium. Study of patients at rest, with exercise and during angina pectoris. N Engl J Med 288 (1973) 809-812
2. Zaret B.L., Stenson R.E., Martin N.D., et al. Potassium-43 myocardial perfusion scanning for the noninvasive evaluation of patients with false-positive exercise tests. Circulation 48 (1973) 1234-1241
3. Ishii Y., MacIntyre W.J., Pritchard W.H., et al. Measurement of total myocardial blood flow in dogs with 43K and the scintillation camera. Circ Res 33 (1973) 113-122
4. Botti R.E., MacIntyre W.J., and Pritchard W.H. Identification of ischemic area of left ventricle by visualization of 43 K myocardial deposition. Circulation 47 (1973) 486-492
5. Zaret B.L., Pitt B., and Ross R.S. Determination of the site, extent, and significance of regional ventricular dysfunction during acute myocardial infarction. Circulation 45 (1972) 441-456
6. Bennett K.R., Smith R.O., Lehan P.H., et al. Correlation of myocardial 42 K uptake with coronary arteriography. Radiology 102 (1972) 117-124
7. Strauss H.W., Zaret B.L., Hurley P.J., et al. A scintiphotographic method for measuring left ventricular ejection fraction in man without cardiac catheterization. Am J Cardiol 28 (1971) 575-580
8. Zaret B.L., Strauss H.W., Hurley P.J., et al. A noninvasive scintiphotographic method for detecting regional ventricular dysfunction in man. N Engl J Med 284 (1971) 1165-1170
9. Brindis R.G., Douglas P.S., Hendel R.C., et al. ACCF/ASNC Appropriateness Criteria for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI). a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology Endorsed by the American Heart Association. J Am Coll Cardiol 46 (2005) 1587-1605
10. Patel M.R., Spertus J.A., Brindis R.G., et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 46 (2005) 1606-1613
11. Kiat H., Maddahi J., Roy L.T., et al. Comparison of technetium 99m methoxy isobutyl isonitrile and thallium 201 for evaluation of coronary artery disease by planar and tomographic methods. Am Heart J 117 (1989) 1-11
12. Benoit T., Vivegnis D., Lahiri A., et al. Tomographic myocardial imaging with technetium-99m tetrofosmin. Comparison with tetrofosmin and thallium planar imaging and with angiography. Eur Heart J 17 (1996) 635-642
13. Cramer M.J., van der Wall E.E., Verzijlbergen J.F., et al. SPECT versus planar 99mTc-sestamibi myocardial scintigraphy. comparison of accuracy and impact on patient management in chronic ischemic heart disease. Q J Nucl Med 41 (1997) 1-9
14. Kapur A., Latus K.A., Davies G., et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice. the ROBUST study. Eur J Nucl Med Mol Imaging 29 (2002) 1608-1616
15. Acampa W., Cuocolo A., Sullo P., et al. Direct comparison of technetium 99m-sestamibi and technetium 99m-tetrofosmin cardiac single photon emission computed tomography in patients with coronary artery disease. J Nucl Cardiol 5 (1998) 265-274
16. Turgut B., Unlu M., and Cengel A. Dobutamine stress tetrofosmin SPECT; evaluation of short rest-stress protocol and head to head comparison with MIBI in detection of coronary artery disease. Ann Nucl Med 19 (2005) 115-122
17. Soman P., Taillefer R., DePuey E.G., et al. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 37 (2001) 458-462
18. Tartagni F., Dondi M., Limonetti P., et al. Dipyridamole technetium-99m-2-methoxy isobutyl isonitrile tomoscintigraphic imaging for identifying diseased coronary vessels. comparison with thallium-201 stress-rest study. J Nucl Med 32 (1991) 369-376
19. Dondi M., Monetti N., Levorato M., et al. Diagnostic accuracy of single photon emission computed tomography with thallium-201 for the identification of diseased coronary arteries. Comparison between dipyridamole infusion and exercise stress test. J Nucl Med Allied Sci 34 (1990) 19-23
20. Huikuri H.V., Korhonen U.R., Airaksinen J., et al. Comparison of dipyridamole-handgrip test and bicycle exercise test for thallium tomographic imaging. Am J Cardiol 61 (1988) 264-268
21. Gupta N.C., Esterbrooks D.J., Hilleman D.E., et al., The GE SPECT Multicenter Adenosine Study Group. Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. J Am Coll Cardiol 19 (1992) 248-257
22. Nguyen T., Heo J., Ogilby J.D., et al. Single photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia. correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography. J Am Coll Cardiol 16 (1990) 1375-1383
23. LaManna M.M., Mohama R., Slavich III I.L., et al. Intravenous adenosine (adenoscan) versus exercise in the noninvasive assessment of coronary artery disease by SPECT. Clin Nucl Med 15 (1990) 804-805
24. Coyne E.P., Belvedere D.A., Vande Streek P.R., et al. Thallium-201 scintigraphy after intravenous infusion of adenosine compared with exercise thallium testing in the diagnosis of coronary artery disease. J Am Coll Cardiol 17 (1991) 1289-1294
25. Nishimura S., Mahmarian J.J., Boyce T.M., et al. Equivalence between adenosine and exercise thallium-201 myocardial tomography. a multicenter, prospective, crossover trial. J Am Coll Cardiol 20 (1992) 265-275
26. Marwick T., Willemart B., D'Hondt A.M., et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 87 (1993) 345-354
27. Cuocolo A., Nicolai E., Soricelli A., et al. Technetium 99m-labeled tetrofosmin myocardial tomography in patients with coronary artery disease. comparison between adenosine and dynamic exercise stress testing. J Nucl Cardiol 3 (1996) 194-203
28. Burns R.J., Galligan L., Wright L.M., et al. Improved specificity of myocardial thallium-201 single-photon emission computed tomography in patients with left bundle branch block by dipyridamole. Am J Cardiol 68 (1991) 504-508
29. Vaduganathan P., He Z.X., Raghavan C., et al. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block. exercise, adenosine or dobutamine imaging?. J Am Coll Cardiol 28 (1996) 543-550
30. Mahmood S., Gupta N.K., Gunning M., et al. 201Tl myocardial perfusion SPET. adenosine alone or combined with dynamic exercise. Nucl Med Commun 15 (1994) 586-592
31. Cramer M.J., Verzijlbergen J.F., van der Wall E.E., et al. Comparison of adenosine and high-dose dipyridamole both combined with low-level exercise stress for 99Tcm-MIBI SPET myocardial perfusion imaging. Nucl Med Commun 17 (1996) 97-104
32. Samady H., Wackers F.J., Joska T.M., et al. Pharmacologic stress perfusion imaging with adenosine. role of simultaneous low-level treadmill exercise. J Nucl Cardiol 9 (2002) 188-196
33. Udelson J.E., Heller G.V., Wackers F.J., et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 109 (2004) 457-464
34. Hendel R.C., Bateman T.M., Cerqueira M.D., et al. Initial Clinical experience with Regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46 (2005) 2069-2075
35. Hays J.T., Mahmarian J.J., Cochran A.J., et al. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 21 (1993) 1583-1590
36. Voth E., Baer F.M., Theissen P., et al. Dobutamine 99mTc-MIBI single-photon emission tomography. non-exercise-dependent detection of haemodynamically significant coronary artery stenoses. Eur J Nucl Med 21 (1994) 537-544
37. Elhendy A., Sozzi F.B., Valkema R., et al. Dobutamine technetium-99m tetrofosmin SPECT imaging for the diagnosis of coronary artery disease in patients with limited exercise capacity. J Nucl Cardiol 7 (2000) 649-654
38. Herman S.D., LaBresh K.A., Santos-Ocampo C.D., et al. Comparison of dobutamine and exercise using technetium-99m sestamibi imaging for the evaluation of coronary artery disease. Am J Cardiol 73 (1994) 164-169
39. Marwick T.H., D'Hondt A.M., Mairesse G.H., et al. Comparative ability of dobutamine and exercise stress in inducing myocardial ischaemia in active patients. Br Heart J 72 (1994) 31-38
40. Geleijnse M.L., Elhendy A., van Domburg R.T., et al. Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. Am J Cardiol 77 (1996) 1057-1061
41. Kiat H., Iskandrian A.S., Villegas B.J., et al. Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system. Multicenter trial for evaluation of safety and diagnostic accuracy. The International Arbutamine Study Group J Am Coll Cardiol 26 (1995) 1159-1167
42. Shehata A.R., Ahlberg A.W., Gillam L.D., et al. Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease. Am J Cardiol 80 (1997) 716-720
43. Wright D.J., Williams S.G., Lindsay H.S., et al. Assessment of adenosine, arbutamine and dobutamine as pharmacological stress agents during (99m)Tc-tetrofosmin SPECT imaging. a randomized study. Nucl Med Commun 22 (2001) 1305-1311
44. Anagnostopoulos C., Pennell D., Francis J., et al. A comparison of adenosine and arbutamine for myocardial perfusion imaging. Eur J Nucl Med 25 (1998) 394-400
45. Milcinski M., Henze E., Lietzenmayer R., et al. Reproducibility of quantitative hexakis-2-methoxyisobutylisonitrile single photon emission tomography in stable coronary artery disease. Eur J Nucl Med 18 (1991) 17-22
46. Mahmarian J.J., Moye L.A., Verani M.S., et al. High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. Am J Cardiol 75 (1995) 1116-1119
47. Germano G., Kavanagh P.B., Waechter P., et al. A new algorithm for the quantitation of myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Med 41 (2000) 712-719
48. Tamaki N., Yonekura Y., Mukai T., et al. Stress thallium-201 transaxial emission computed tomography. quantitative versus qualitative analysis for evaluation of coronary artery disease. J Am Coll Cardiol 4 (1984) 1213-1221
49. DePasquale E.E., Nody A.C., DePuey E.G., et al. Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease. Circulation 77 (1988) 316-327
50. Mahmarian J.J., Boyce T.M., Goldberg R.K., et al. Quantitative exercise thallium-201 single photon emission computed tomography for the enhanced diagnosis of ischemic heart disease. J Am Coll Cardiol 15 (1990) 318-329
51. Mowatt G., Brazzelli M., Gemmell H., et al. Systematic review of the prognostic effectiveness of SPECT myocardial perfusion scintigraphy in patients with suspected or known coronary artery disease and following myocardial infarction. Nucl Med Commun 26 (2005) 217-229
52. Iskander S., and Iskandrian A.E. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 32 (1998) 57-62
53. Marie P.Y., Danchin N., Durand J.F., et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol 26 (1995) 879-886
54. Machecourt J., Longere P., Fagret D., et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. Study in 1,926 patients with follow-up at 33 months. J Am Coll Cardiol 23 (1994) 1096-1106
55. Schinkel A.F., Elhendy A., Biagini E., et al. Prognostic stratification using dobutamine stress 99mTc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testing. J Nucl Med 46 (2005) 12-18
56. Shaw L.J., Hendel R., Borges-Neto S., et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging. results from the multicenter registry of 4,728 patients. J Nucl Med 44 (2003) 134-139
57. Hachamovitch R., Hayes S., Friedman J.D., et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans. what is the warranty period of a normal scan?. J Am Coll Cardiol 41 (2003) 1329-1340
58. Alkeylani A., Miller D.D., Shaw L.J., et al. Influence of race on the prediction of cardiac events with stress technetium-99m sestamibi tomographic imaging in patients with stable angina pectoris. Am J Cardiol 81 (1998) 293-297
59. Elhendy A., Schinkel A.F., van Domburg R.T., et al. Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction. impact of scintigraphic extent of coronary artery disease. J Nucl Cardiol 11 (2004) 704-709
60. Leslie W.D., Tully S.A., Yogendran M.S., et al. Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging. J Nucl Med 46 (2005) 204-211
61. Hachamovitch R., Hayes S.W., Friedman J.D., et al. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol 45 (2005) 722-729
62. Hachamovitch R., Berman D.S., Shaw L.J., et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death. differential stratification for risk of cardiac death and myocardial infarction. Circulation 97 (1998) 535-543
63. Borges-Neto S., Shaw L.K., Tuttle R.H., et al. Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol 95 (2005) 182-188
64. Hachamovitch R., Hayes S.W., Friedman J.D., et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107 (2003) 2900-2907
65. Elhendy A., Schinkel A.F., van Domburg R.T., et al. Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease. J Nucl Cardiol 11 (2004) 527-533
66. Valeti U.S., Miller T.D., Hodge D.O., et al. Exercise single-photon emission computed tomography provides effective risk stratification of elderly men and elderly women. Circulation 111 (2005) 1771-1776
67. Patel G.M., Hauser T.H., Parker J.A., et al. Quantitative relationship of stress Tc-99m sestamibi lung uptake with resting Tl-201 lung uptake and with indices of left ventricular dysfunction and coronary artery disease. J Nucl Cardiol 11 (2004) 408-413
68. Romanens M., Gradel C., Saner H., et al. Comparison of 99mTc-sestamibi lung/heart ratio, transient ischaemic dilation and perfusion defect size for the identification of severe and extensive coronary artery disease. Eur J Nucl Med 28 (2001) 907-910
69. Bacher-Stier C., Sharir T., Kavanagh P.B., et al. Postexercise lung uptake of 99mTc-sestamibi determined by a new automatic technique. validation and application in detection of severe and extensive coronary artery disease and reduced left ventricular function. J Nucl Med 41 (2000) 1190-1197
70. Daou D., Delahaye N., Vilain D., et al. Identification of extensive coronary artery disease. incremental value of exercise Tl-201 SPECT to clinical and stress test variables. J Nucl Cardiol 9 (2002) 161-168
71. Abidov A., Bax J.J., Hayes S.W., et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. J Am Coll Cardiol 42 (2003) 1818-1825
72. Abidov A., Bax J.J., Hayes S.W., et al. Integration of automatically measured transient ischemic dilation ratio into interpretation of adenosine stress myocardial perfusion SPECT for detection of severe and extensive CAD. J Nucl Med 45 (2004) 1999-2007
73. Daou D., Coaguila C., Delahaye N., et al. Discordance between exercise SPECT lung Tl-201 uptake and left ventricular transient ischemic dilation in patients with CAD. J Nucl Cardiol 11 (2004) 53-61
74. Hansen C.L., Cen P., Sanchez B., et al. Comparison of pulmonary uptake with transient cavity dilation after dipyridamole Tl-201 perfusion imaging. J Nucl Cardiol 9 (2002) 47-51
75. Hansen C.L., Sangrigoli R., Nkadi E., et al. Comparison of pulmonary uptake with transient cavity dilation after exercise thallium-201 perfusion imaging. J Am Coll Cardiol 33 (1999) 1323-1327
76. Forster T., McNeill A.J., Salustri A., et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 21 (1993) 1591-1596
77. Smart S., Wynsen J., and Sagar K. Dobutamine-atropine stress echocardiography for reversible dysfunction during the first week after acute myocardial infarction. limitations and determinants of accuracy. J Am Coll Cardiol 30 (1997) 1669-1678
78. Geleijnse M.L., Vigna C., Kasprzak J.D., et al. Usefulness and limitations of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in patients with left bundle branch block. A multicentre study. Eur Heart J 21 (2000) 1666-1673
79. Gottdiener J.S. Overview of stress echocardiography. uses, advantages, and limitations. Prog Cardiovasc Dis 43 (2001) 315-334
80. Acampa W., Spinelli L., Petretta M., et al. Prognostic value of myocardial ischemia in patients with uncomplicated acute myocardial infarction. direct comparison of stress echocardiography and myocardial perfusion imaging. J Nucl Med 46 (2005) 417-423
81. Le Feuvre C.L., Barthelemy O., Dubois-Laforgue D., et al. Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with type 2 diabetes. Diabetes Metab 31 (2005) 135-142
82. Links J.M., DePuey E.G., Taillefer R., et al. Attenuation correction and gating synergistically improve the diagnostic accuracy of myocardial perfusion SPECT. J Nucl Cardiol 9 (2002) 183-187
83. Heller G.V., Bateman T.M., Johnson L.L., et al. Clinical value of attenuation correction in stress-only Tc-99m sestamibi SPECT imaging. J Nucl Cardiol 11 (2004) 273-281
84. Hendel R.C., Berman D.S., Cullom S.J., et al. Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Circulation 99 (1999) 2742-2749
85. Araujo L.I., Jimenez-Hoyuela J.M., McClellan J.R., et al. Improved uniformity in tomographic myocardial perfusion imaging with attenuation correction and enhanced acquisition and processing. J Nucl Med 41 (2000) 1139-1144
86. Kjaer A., Cortsen A., Rahbek B., et al. Attenuation and scatter correction in myocardial SPET. improved diagnostic accuracy in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging 29 (2002) 1438-1442
87. Banzo I., Pena F.J., Allende R.H., et al. Prospective clinical comparison of non-corrected and attenuation- and scatter-corrected myocardial perfusion SPECT in patients with suspicion of coronary artery disease. Nucl Med Commun 24 (2003) 995-1002
88. Narayanan M.V., King M.A., Pretorius P.H., et al. Human-observer receiver-operating-characteristic evaluation of attenuation, scatter, and resolution compensation strategies for (99m)Tc myocardial perfusion imaging. J Nucl Med 44 (2003) 1725-1734
89. Grossman G.B., Garcia E.V., Bateman T.M., et al. Quantitative Tc-99m sestamibi attenuation-corrected SPECT. development and multicenter trial validation of myocardial perfusion stress gender-independent normal database in an obese population. J Nucl Cardiol 11 (2004) 263-272
90. Fricke E., Fricke H., Weise R., et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT. evaluation of the method by comparison with perfusion PET. J Nucl Med 46 (2005) 736-744
91. Utsunomiya D., Tomiguchi S., Shiraishi S., et al. Initial experience with X-ray CT based attenuation correction in myocardial perfusion SPECT imaging using a combined SPECT/CT system. Ann Nucl Med 19 (2005) 485-489
92. Masood Y., Liu Y.-H., DePuey E.G., et al. Clinical validation of attenuation correction using X-ray computed tomography-derived attenuation maps. Multicenter clinical trial with angiographic correlation. J Nucl Cardiol (2005) (in press)
93. Takahashi Y., Murase K., Higashino H., et al. Attenuation correction of myocardial SPECT images with X-ray CT. effects of registration errors between X-ray CT and SPECT. Ann Nucl Med 16 (2002) 431-435
94. Loghin C., Sdringola S., and Gould K.L. Common artifacts in PET myocardial perfusion images due to attenuation-emission misregistration. clinical significance, causes, and solutions. J Nucl Med 45 (2004) 1029-1039
95. Go R.T., Marwick T.H., MacIntyre W.J., et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 31 (1990) 1899-1905
96. MacIntyre W.J., Go R.T., King J.L., et al. Clinical outcome of cardiac patients with negative thallium-201 SPECT and positive rubidium-82 PET myocardial perfusion imaging. J Nucl Med 34 (1993) 400-404
97. Marwick T.H., Shan K., Patel S., et al. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol 80 (1997) 865-870
98. Chow B.J.W., Wong J.W., Yoshinaga K., et al. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. J Nucl Med 46 (2005) 1095-1101
99. Chow B.J., Ananthasubramaniam K., deKemp R.A., et al. Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography. J Am Coll Cardiol 45 (2005) 1227-1234
100. Van Tosh A., Garza D., Roberti R., et al. Serial myocardial perfusion imaging with dipyridamole and rubidium-82 to assess restenosis after angioplasty. J Nucl Med 36 (1995) 1553-1560
101. El Fakhri G., Sitek A., Guerin B., et al. Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. J Nucl Med 46 (2005) 1264-1271
102. Parkash R., deKemp R.A., Ruddy T.D., et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 11 (2004) 440-449
103. Lin J.W., Sciacca R.R., Chou R.L., et al. Quantification of myocardial perfusion in human subjects using 82Rb and wavelet-based noise reduction. J Nucl Med 42 (2001) 201-208
104. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, TX
105. Barbash G.I., White H.D., Modan M., et al., Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 22 (1993) 707-713
106. Kodama K., Sakagashira S., and Hori M. Prognostic significance of diabetes mellitus in patients with acute myocardial infarction after recanalization. Diabetes Res Clin Pract 30 (1996) 71-75
107. Silva J.A., Ramee S.R., White C.J., et al. Primary stenting in acute myocardial infarction. influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 138 (1999) 446-455
108. Granger C.B., Califf R.M., Young S., et al., The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 21 (1993) 920-925
109. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
110. Kang X., Berman D.S., Lewin H., et al. Comparative ability of myocardial perfusion sing-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J 137 (1999) 949-957
111. Zarich S.W., Cohen M.C., Lane S.E., et al. Routine perioperative dipyridamole 201Tl imaging in diabetic patients undergoing vascular surgery. Diabetes Care 19 (1996) 355-360
112. De Lorenzo A., Lima R.S., Siqueira-Filho A.G., et al. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 90 (2002) 827-832
113. Wackers F.J., Young L.H., Inzucchi S.E., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects. the DIAD study. Diabetes Care 27 (2004) 1954-1961
114. Araz M., Celen Z., Akdemir I., et al. Frequency of silent myocardial ischemia in type 2 diabetic patients and the relation with poor glycemic control. Acta Diabetol 41 (2004) 38-43
115. Zellweger M.J., Hachamovitch R., Kang X., et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 25 (2004) 543-550
116. Yasuda I., Kawakami K., Shimada T., et al. Systolic and diastolic left ventricular dysfunction in middle-aged asymptomatic non-insulin-dependent diabetics. J Cardiol 22 (1992) 427-438
117. Takahashi N., Iwasaka T., Sugiura T., et al. Diastolic time in diabetes. Impairment of diastolic time during dynamic exercise in type 2 diabetes with retinopathy. Chest 100 (1991) 748-753
118. Arora G.D., Reeves W.C., and Movahed A. Alteration of coronary perfusion reserve in hypertensive patients with diabetes. J Hum Hypertens 8 (1994) 51-57
119. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease. a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108 (2003) 2154-2169
120. Dahan M., Viron B.M., Faraggi M., et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 54 (1998) 255-262
121. Patel A.D., Abo-Auda W.S., Davis J.M., et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol 92 (2003) 146-151
122. Feola M., Biggi A., Ribichini F., et al. Predicting cardiac events with Tl201 dipyridamole myocardial scintigraphy in renal transplant recipients. J Nephrol 15 (2002) 48-53
123. De Lima J.J., Sabbaga E., Vieira M.L., et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 42 (2003) 263-268
124. Dussol B., Bonnet J.L., Sampol J., et al. Prognostic value of inducible myocardial ischemia in predicting cardiovascular events after renal transplantation. Kidney Int 66 (2004) 1633-1639
125. Hase H., Joki N., Ishikawa H., et al. Prognostic value of stress myocardial perfusion imaging using adenosine triphosphate at the beginning of haemodialysis treatment in patients with end-stage renal disease. Nephrol Dial Transplant 19 (2004) 1161-1167
126. Yao S.S., Qureshi E., Nichols K., et al. Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Clin Cardiol 27 (2004) 615-620
127. Danias P.G., Papaioannou G.I., Ahlberg A.W., et al. Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. Am J Cardiol 94 (2004) 14-19
128. Sciagra R., Giaccardi M., Porciani M.C., et al. Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med 45 (2004) 164-168
129. Vaccarino V., Parsons L., Every N.R., et al., The National Registry of Myocardial Infarction P. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 341 (1999) 217-225
130. Mieres J.H., Shaw L.J., and Hendel R.C. Consensus statement from the American Society of Nuclear Cardiology Task Force on Women and Heart Disease. The role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. J Nucl Cardiol 10 (2003) 95-101
131. Santana-Boado C., Candell-Riera J., and Castell C. Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men. J Nucl Med 39 (1998) 751-755
132. Friedman T.D., Greene A.C., and Iskandrain A.S. Exercise thallium-201 myocardial perfusion scintigraphy in women. correlation with coronary arteriography. Am J Cardiol 49 (1982) 1632-1637
133. Amanullah A.M., Berman D.S., and Hachamovitch R. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Am J Cardiol 80 (1997) 132-137
134. Hachamovitch R., Berman D.S., and Kiat H. Effective risk stratification using exercise myocardial perfusion SPECT in women. gender-related differences in prognostic nuclear testing. J Am Coll Cardiol 28 (1996) 34-44
135. Goodgold H.M., Rehder J.G., Samuels L.D., et al. Improved interpretation of exercise Tl-201 myocardial perfusion scintigraphy in women. characterization of breast attenuation artifacts. Radiology 165 (1987) 361-366
136. Hansen C.L., Crabbe D., and Rubin S. Lower diagnostic accuracy of thallium-201 SPECT myocardial perfusion imaging in women. an effect of smaller chamber. J Am Coll Cardiol 67 (1996) 69-77
137. Taillefer R., DePuey E.G., and Udelson J.E. Diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 29 (1997) 69-77
138. Akinboboye O.O., Idris O., Onwuanyi A., et al. Incidence of major cardiovascular events in black patients with normal myocardial stress perfusion study results. J Nucl Cardiol 8 (2001) 541-547
139. Shaw L.J., Hendel R.C., Cerquiera M., et al. Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 45 (2005) 1494-1504
140. Lowry P.J., Glover D.R., Mace P.J., et al. Coronary artery disease in Asians in Birmingham. Br Heart J 52 (1984) 610-613
141. Liew C.F., Seah E.S., Yeo K.P., et al. Lean, nondiabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes Relat Metab Disord 27 (2003) 784-789
142. Hughes L.O., Raval U., and Raftery E.B. First myocardial infarctions in Asian and white men. Br Med J 298 (1989) 1345-1350
143. Galasko G.I., Senior R., and Lahiri A. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community. the Harrow heart failure watch. Heart 91 (2005) 595-600
144. Dhawan J., Bray C.L., Warburton R., et al. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?. Br Heart J 72 (1994) 413-421
145. Saha N., Tong M.C., Tay J.S., et al. DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients. Clin Genet 42 (1992) 164-170
146. Hammermeister K.E., DeRouen T.A., and Dodge H.T. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 59 (1979) 421-430
147. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 309 (1983) 331-367
148. Zaret B.L., Wackers F.J., Terrin M.L., et al. Value of radionuclide rest and exercise left ventricular ejection fraction to access survival of patients following thrombolytic therapy for acute myocardial infarction. results of the Thrombolysis in Myocardial Infarction (TIMI) phase II study. J Am Coll Cardiol 26 (1995) 73-79
149. Kober L., Torp-Pedersen C., Pedersen O.D., et al. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 78 (1996) 1124-1128
150. O'Connor C.M., Hathaway W.R., Bates E.R., et al. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction. development of a predictive model. Am Heart J 133 (1997) 663-673
151. Yang K.T., and Chen H.D. A semi-automated method for edge detection in the evaluation of left ventricular function using ECG-gated single-photon emission tomography. Eur J Nucl Med 21 (1994) 1206-1211
152. Najm Y.C., Timmis A.D., Maisey M.N., et al. The evaluation of ventricular function using gated myocardial imaging with Tc-99m MIBI. Eur Heart J 10 (1989) 142-148
153. DePuey E.G., Nichols K., and Dobrinsky C. Left ventricular ejection fraction assessed from gated technetium-99m-sestamibi SPECT. J Nucl Med 34 (1993) 1871-1876
154. Boonyaprapa S., Ekmahachai M., Thanachaikun N., et al. Measurement of left ventricular ejection fraction from gated technetium-99m sestamibi myocardial images. Eur J Nucl Med 22 (1995) 528-531
155. Germano G., Kiat H., Kavanagh P.B., et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 36 (1995) 2138-2147
156. Everaert H., Franken P.R., Flamen P., et al. Left ventricular ejection fraction from gated SPET myocardial perfusion studies. a method based on the radial distribution of count rate density across the myocardial wall. Eur J Nucl Med 23 (1996) 1628-1633
157. Smith W.H., Kastner R.J., Calnon D.A., et al. Quantitative gated single photon emission computed tomography imaging. a counts-based method for display and measurement of regional and global ventricular systolic function. J Nucl Cardiol 4 (1997) 451-463
158. Brigger P., Bacharach S.L., Srinivasan G., et al. Segmentation of gated Tl-SPECT images and computation of ejection fraction. a different approach. J Nucl Cardiol 6 (1999) 286-297
159. Liu Y.H., Sinusas A.J., Khaimov D., et al. New hybrid count- and geometry-based method for quantification of left ventricular volumes and ejection fraction from ECG-gated SPECT. methodology and validation. J Nucl Cardiol 12 (2005) 55-65
160. Itti E., Rosso J., Hammami H., et al. Myocardial tracking, a new method to calculate ejection fraction with gated SPECT. validation with 201Tl versus planar angiography. J Nucl Med 42 (2001) 845-852
161. He Z.X., Cwajg E., Preslar J.S., et al. Accuracy of left ventricular ejection fraction determined by gated myocardial perfusion SPECT with Tl-201 and Tc-99m sestamibi. comparison with first-pass radionuclide angiography. J Nucl Cardiol 6 (1999) 412-417
162. Williams K.A., and Taillon L.A. Left ventricular function in patients with coronary artery disease assessed by gated tomographic myocardial perfusion images. Comparison with assessment by contrast ventriculography and first-pass radionuclide angiography. J Am Coll Cardiol 27 (1996) 173-181
163. Calnon D.A., Kastner R.J., Smith W.H., et al. Validation of a new counts-based gated single photon emission computed tomography method for quantifying left ventricular systolic function. comparison with equilibrium radionuclide angiography. J Nucl Cardiol 4 (1997) 464-471
164. Chua T., Kiat H., Germano G., et al. Gated technetium-99m sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability. Correlation with echocardiography and rest thallium-201 scintigraphy. J Am Coll Cardiol 23 (1994) 1107-1114
165. Vaduganathan P., He Z.X., Vick III G.W., et al. Evaluation of left ventricular wall motion, volumes, and ejection fraction by gated myocardial tomography with technetium 99m-labeled tetrofosmin. a comparison with cine magnetic resonance imaging. J Nucl Cardiol 6 (1999) 3-10
166. Vallejo E., Dione D.P., Sinusas A.J., et al. Assessment of left ventricular ejection fraction with quantitative gated SPECT. accuracy and correlation with first-pass radionuclide angiography. J Nucl Cardiol 7 (2000) 461-470
167. Navare S.M., Wackers F.J., and Liu Y.H. Comparison of 16-frame and 8-frame gated SPET imaging for determination of left ventricular volumes and ejection fraction. Eur J Nucl Med Mol Imaging 30 (2003) 1330-1337
168. Vallejo E., Dione D.P., Bruni W.L., et al. Reproducibility and accuracy of gated SPECT for determination of left ventricular volumes and ejection fraction. experimental validation using MRI. J Nucl Med 41 (2000) 874-882 discussion 883-6
169. Manrique A., Faraggi M., Vera P., et al. 201Tl and 99mTc-MIBI gated SPECT in patients with large perfusion defects and left ventricular dysfunction. comparison with equilibrium radionuclide angiography. J Nucl Med 40 (1999) 805-809
170. DePuey E.G., Parmett S., Ghesani M., et al. Comparison of Tc-99m sestamibi and Tl-201 gated perfusion SPECT. J Nucl Cardiol 6 (1999) 278-285
171. Smanio P.E., Watson D.D., Segalla D.L., et al. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol 30 (1997) 1687-1692
172. Links J.M., DePuey E.G., Taillefer R., et al. Attenuation correction and gating synergistically improve the diagnostic accuracy of myocardial perfusion SPECT. J Nucl Cardiol 9 (2002) 183-187
173. Johnson L.L., Verdesca S.A., Aude W.Y., et al. Postischemic stunning can affect left ventricular ejection fraction and regional wall motion on post-stress gated sestamibi tomograms. J Am Coll Cardiol 30 (1997) 1641-1648
174. Sakamoto K., Nakamura T., Zen K., et al. Identification of exercise-induced left ventricular systolic and diastolic dysfunction using gated SPECT in patients with coronary artery disease. J Nucl Cardiol 11 (2004) 152-158
175. Liao L., Smith W.T., Tuttle R.H., et al. Prediction of death and nonfatal myocardial infarction in high-risk patients. a comparison between the Duke treadmill score, peak exercise radionuclide angiography, and SPECT perfusion imaging. J Nucl Med 46 (2005) 5-11
176. Van Kriekinge S.D., Berman D.S., and Germano G. Automatic quantification of left ventricular ejection fraction from gated blood pool SPECT. J Nucl Cardiol 6 (1999) 498-506
177. Kim S.J., Kim I.J., Kim Y.S., et al. Gated blood pool SPECT for measurement of left ventricular volumes and left ventricular ejection fraction. comparison of 8 and 16 frame gated blood pool SPECT. Int J Cardiovasc Imaging 21 (2005) 261-266
178. Higuchi T., Taki J., Nakajima K., et al. Left ventricular ejection and filling rate measurement based on the automatic edge detection method of ECG-gated blood pool single-photon emission tomography. Ann Nucl Med 18 (2004) 507-511
179. Nichols K., Humayun N., De Bondt P., et al. Model dependence of gated blood pool SPECT ventricular function measurements. J Nucl Cardiol 11 (2004) 282-292
180. Vanhove C., Franken P.R., Defrise M., et al. Comparison of 180 degrees and 360 degrees data acquisition for determination of left ventricular function from gated myocardial perfusion tomography and gated blood pool tomography. Eur J Nucl Med Mol Imaging 30 (2003) 1498-1504
181. Akinboboye O., Nichols K., Yang Y., et al. Accuracy of radionuclide ventriculography assessed by magnetic resonance imaging in patients with abnormal left ventricles. J Nucl Cardiol 12 (2005) 418-427
182. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 32 (1998) 948-954
183. Di Salvo T.G., Mathier M., Semigran M.J., et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 25 (1995) 1143-1153
184. Daou D., Van Kriekinge S.D., Coaguila C., et al. Automatic quantification of right ventricular function with gated blood pool SPECT. J Nucl Cardiol 11 (2004) 293-304
185. Kim S.J., Kim I.J., Kim Y.S., et al. Automatic quantification of right ventricular volumes and right ventricular ejection fraction with gated blood pool SPECT. comparison of 8- and 16-frame gated blood pool SPECT with first-pass radionuclide angiography. J Nucl Cardiol 12 (2005) 553-559
186. Groch M.W., Marshall R.C., Erwin W.D., et al. Quantitative gated blood pool SPECT for the assessment of coronary artery disease at rest. J Nucl Cardiol 5 (1998) 567-573
187. Groch M.W., Schippers D.J., Marshall R.C., et al. Quantitative gated blood pool SPECT. analysis of 3-dimensional models for the assessment of regional myocardial wall motion. J Nucl Cardiol 9 (2002) 271-284
188. Casset-Senon D., Philippe L., Babuty D., et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy by Fourier analysis of gated blood pool single-photon emission tomography. Am J Cardiol 82 (1998) 1399-1404
189. Chevalier P., Bontemps L., Fatemi M., et al. Gated blood-pool SPECT evaluation of changes after radiofrequency catheter ablation of accessory pathways. evidence for persistent ventricular preexcitation despite successful therapy. J Am Coll Cardiol 34 (1999) 1839-1846
190. Fauchier L., Marie O., Casset-Senon D., et al. Ventricular dyssynchrony and risk markers of ventricular arrhythmias in nonischemic dilated cardiomyopathy. a study with phase analysis of angioscintigraphy. Pacing Clin Electrophysiol 26 (2003) 352-356
191. Adachi I., Akagi H., Umeda T., et al. Gated blood pool SPECT improves reproducibility of right and left ventricular Fourier phase analysis in radionuclide angiography. Ann Nucl Med 17 (2003) 711-716
192. Kasama S., Toyama T., Hoshizaki H., et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 122 (2002) 542-548
193. Pigott J.D., Kouchoukos N.T., Oberman A., et al. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol 5 (1985) 1036-1045
194. Marwick T.H. The viable myocardium. epidemiology, detection, and clinical implications. Lancet 351 (1998) 815-819
195. Acampa W., Petretta M., Spinelli L., et al. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging 32 (2005) 430-437
196. Meluzin J., Cerny J., Spinarova L., et al. Prognosis of patients with chronic coronary artery disease and severe left ventricular dysfunction. The importance of myocardial viability. Eur J Heart Fail 5 (2003) 85-93
197. Bonow R.O., and Dilsizian V. Thallium 201 for assessment of myocardial viability. Semin Nucl Med 21 (1991) 230-241
198. Schinkel A.F., Bax J.J., Sozzi F.B., et al. Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. Heart 88 (2002) 125-130
199. Tillisch J., Brunken R., Marshall R., et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314 (1986) 884-888
200. Marwick T.H., MacIntyre W.J., Lafont A., et al. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation 85 (1992) 1347-1353
201. Gerber B.L., Vanoverschelde J.L., Bol A., et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 94 (1996) 651-659
202. Tamaki N., Yonekura Y., Yamashita K., et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 64 (1989) 860-865
203. Gropler R.J., Geltman E.M., Sampathkumaran K., et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 22 (1993) 1587-1597
204. Maes A.F., Borgers M., Flameng W., et al. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol 29 (1997) 62-68
205. Tamaki N., Kawamoto M., Tadamura E., et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 91 (1995) 1697-1705
206. Knuuti M.J., Saraste M., Nuutila P., et al. Myocardial viability. fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 127 (1994) 785-796
207. Baer F.M., Voth E., Deutsch H.J., et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 28 (1996) 60-69
208. Lucignani G., Paolini G., Landoni C., et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 19 (1992) 874-881
209. Carrel T., Jenni R., Haubold-Reuter S., et al. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 6 (1992) 479-484
210. Bax J.J., Wijns W., Cornel J.H., et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease. comparison of pooled data. J Am Coll Cardiol 30 (1997) 1451-1460
211. Di Carli M.F., Davidson M., Little R., et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 73 (1994) 527-533
212. Lee K.S., Marwick T.H., Cook S.A., et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 90 (1994) 2687-2694
213. vom Dahl J., Altehoefer C., Sheehan F.H., et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 38 (1997) 742-748
214. Bax J.J., Patton J.A., Poldermans D., et al. 18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography. cardiac applications. Semin Nucl Med 30 (2000) 281-298
215. Di Carli M.F., Asgarzadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 92 (1995) 3436-3444
216. Eitzman D., al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 20 (1992) 559-565
217. Samady H., Elefteriades J.A., Abbott B.G., et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 100 (1999) 1298-1304
218. Sandler M.P., Bax J.J., Patton J.A., et al. Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera. J Nucl Med 39 (1998) 2035-2043
219. Sandler M.P., and Patton J.A. Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography. an alternative for determining myocardial viability. J Nucl Cardiol 3 (1996) 342-349
220. Huitink J.M., Visser F.C., Bax J.J., et al. Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction. Am J Cardiol 81 (1998) 1072-1077
221. Huitink J.M., Visser F.C., van Lingen A., et al. Feasibility of planar fluorine-18-FDG imaging after recent myocardial infarction to assess myocardial viability. J Nucl Med 36 (1995) 975-981
222. Kalff V., Berlangieri S.U., Van Every B., et al. Is planar thallium-201/fluorine-18 fluorodeoxyglucose imaging a reasonable clinical alternative to positron emission tomographic myocardial viability scanning?. Eur J Nucl Med 22 (1995) 625-632
223. Burt R.W., Perkins O.W., Oppenheim B.E., et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 36 (1995) 176-179
224. Martin W.H., Delbeke D., Patton J.A., et al. FDG-SPECT. correlation with FDG-PET. J Nucl Med 36 (1995) 988-995
225. Bax J.J., Cornel J.H., Visser F.C., et al. Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization. J Nucl Med 39 (1998) 1481-1486
226. Chen E.Q., MacIntyre W.J., Go R.T., et al. Myocardial viability studies using fluorine-18-FDG SPECT. a comparison with fluorine-18-FDG PET. J Nucl Med 38 (1997) 582-586
227. 18F]Fluorodeoxyglucose single photon emission computed tomography. Can it replace PET and thallium SPECT for the assessment of myocardial viability?. Circulation 97 (1998) 843-850
228. Bax J., Cornel J., Visser F., et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 30 (1997) 377-383
229. Bax J.J., Cornel J.H., Visser F.C., et al. F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. J Nucl Cardiol 4 (1997) 302-308
230. Bonow R.O., Dilsizian V., Cuocolo A., et al. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 83 (1991) 26-37
231. Dilsizian V., Perrone-Filardi P., Arrighi J.A., et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography. Circulation 88 (1993) 941-952
232. Altehoefer C., vom Dahl J., Buell U., et al. Comparison of thallium-201 single-photon emission tomography after rest injection and fluorodeoxyglucose positron emission tomography for assessment of myocardial viability in patients with chronic coronary artery disease. Eur J Nucl Med 21 (1994) 37-45
233. Maddahi J., Schelbert H., Brunken R., et al. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 35 (1994) 707-715
234. Tamaki N., Kawamoto M., Takahashi N., et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction. comparison with stress thallium imaging. J Am Coll Cardiol 22 (1993) 1621-1627
235. Backus M., Piwnica-Worms D., Hockett D., et al. Microprobe analysis of Tc-MIBI in heart cells. calculation of mitochondrial membrane potential. Am J Physiol 265 (1993) C178-C187
236. Piwnica-Worms D., Kronauge J.F., and Chiu M.L. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 32 (1991) 1992-1999
237. Piwnica-Worms D., Kronauge J.F., and Chiu M.L. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82 (1990) 1826-1838
238. Li Q.S., Frank T.L., Franceschi D., et al. Technetium-99m methoxyisobutyl isonitrile (RP30) for quantification of myocardial ischemia and reperfusion in dogs. J Nucl Med 29 (1988) 1539-1548
239. Franceschi M., Guimond J., Zimmerman R.E., et al. Myocardial clearance of Tc-99m hexakis-2-methoxy-2-methylpropyl isonitrile (MIBI) in patients with coronary artery disease. Clin Nucl Med 15 (1990) 307-312
240. Li Q.S., Solot G., Frank T.L., et al. Myocardial redistribution of technetium-99m-methoxyisobutyl isonitrile (SESTAMIBI). J Nucl Med 31 (1990) 1069-1076
241. 201Tl in the presence of a severe coronary artery stenosis. Circulation 89 (1994) 2332-2341
242. Senior R., Kaul S., Raval U., et al. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 9 (2002) 454-462
243. Batista J.F., Pereztol O., Valdes J.A., et al. Improved detection of myocardial perfusion reversibility by rest-nitroglycerin Tc-99m-MIBI. comparison with TI-201 reinjection. J Nucl Cardiol 6 (1999) 480-486
244. Greco C., Ciavolella M., Tanzilli G., et al. Preoperative identification of viable myocardium. effectiveness of nitroglycerine-induced changes in myocardial Sestamibi uptake. Cardiovasc Surg 6 (1998) 149-155
245. Greco C., Tanzilli G., Ciavolella M., et al. Nitroglycerin-induced changes in myocardial sestamibi uptake to detect tissue viability. radionuclide comparison before and after revascularization. Coron Artery Dis 7 (1996) 877-884
246. Kostkiewicz M., Olszowska M., Przewlocki T., et al. Prognostic value of nitrate enhanced Tc99m MIBI SPECT study in detecting viable myocardium in patients with coronary artery disease. Int J Cardiovasc Imaging 19 (2003) 129-135
247. Tzonevska A., Tzvetkov K., Dimitrova M., et al. Assessment of myocardial viability with (99m)Tc-sestamibi-gated SPET images in patients undergoing percutaneous transluminar coronary angioplasty. Hell J Nucl Med 8 (2005) 48-53
248. Duncan B.H., Ahlberg A.W., Levine M.G., et al. Comparison of electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomographic imaging and rest-redistribution thallium-201 in the prediction of myocardial viability. Am J Cardiol 85 (2000) 680-684
249. Kauffman G.J., Boyne T.S., and Watson D.D. Comparison of rest Tl201 imaging and rest tc99m-sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction. J Am Coll Cardiol 27 (1996) 1592-1597
250. Dilsizian V., Arrighi J.A., Diodati J.G., et al. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Circulation 89 (1994) 578-587
251. Soufer R., Dey H.M., Ng C.K., et al. Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. Am J Cardiol 75 (1995) 1214-1219
252. Sawada S.G., Allman K.C., Muzik O., et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 23 (1994) 92-98
253. Young L.H., Li J., Baron S.J., et al. AMP-activated protein kinase. a key stress signaling pathway in the heart. Trends Cardiovasc Med 15 (2005) 110-118
254. He Z.X., Shi R.F., Wu Y.J., et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation 108 (2003) 1208-1213
255. Southworth R., Dearling J.L., Medina R.A., et al. Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart. application of a new autoradiographic technique. Eur J Nucl Med Mol Imaging 29 (2002) 1334-1341
256. McNulty P.H., Jagasia D., Cline G.W., et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation 101 (2000) 917-922
257. Yamamichi Y., Kusuoka H., Morishita K., et al. Metabolism of iodine-123-BMIPP in perfused rat hearts. J Nucl Med 36 (1995) 1043-1050
258. Nohara R., Hosokawa R., Hirai T., et al. Basic kinetics of 15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid (BMIPP) in canine myocardium. Int J Cardiac Imag 15 (1999) 11-20
259. Nishimura T., Nagata S., Uehara T., et al. Prognosis of hypertrophic cardiomyopathy. assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. Ann Nucl Med 10 (1996) 71-78
260. Matsuo S., Nakamura Y., Takahashi M., et al. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J 62 (1998) 167-172
261. Tadamura E., Kudoh T., Hattori N., et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med 39 (1998) 390-396
262. Yazaki Y., Isobe M., Takahashi W., et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT. correlation with clinicopathological findings and clinical course. Heart 81 (1999) 153-159
263. Kitagawa K., Takeda K., Saito K., et al. Differences in fatty acid metabolic disorder between ischemic myocardium and doxorubicin-induced myocardial damage. assessment using BMIPP dynamic SPECT with analysis by the Rutland method. J Nucl Med 43 (2002) 1286-1294
264. Ito T., Hoshida S., Nishino M., et al. Relationship between evaluation by quantitative fatty acid myocardial scintigraphy and response to beta-blockade therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 28 (2001) 1811-1816
265. Yoshinaga K., Tahara M., Torii H., et al. Predicting the effects on patients with dilated cardiomyopathy of beta-blocker therapy, by using iodine-123 15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid (BMIPP) myocardial scintigraphy. Ann Nucl Med 12 (1998) 341-347
266. Fujibayashi Y., Yonekura Y., Takemura Y., et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R, S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 31 (1990) 1818-1822
267. Nishimura M., Hashimoto T., Kobayashi H., et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 66 (2004) 811-819
268. Hosokawa R., Nohara R., Fujibayashi Y., et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion. implications for clinical SPECT. J Nucl Med 38 (1997) 1857-1863
269. Dilsizian V., Bateman T.M., Bergmann S.R., et al. Metabolic imaging with b-methyl-p-[123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 112 (2005) 2169-2174
270. Chikamori T., Fujita H., Nanasato M., et al. Prognostic value of I-123 15-(p-iodophenyl)-3-(R, S) methylpentadecanoic acid myocardial imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 12 (2005) 172-178
271. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
272. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. a randomized controlled trial. JAMA 291 (2004) 309-316
273. Fukuda H., Syrota A., Charbonneau P., et al. Use of 11C-triphenylmethylphosphonium for the evaluation of membrane potential in the heart by positron-emission tomography. Eur J Nucl Med 11 (1986) 478-483
274. Dence C.S., Herrero P., Schwarz S.W., et al. Imaging myocardium enzymatic pathways with carbon-11 radiotracers. Methods Enzymol 385 (2004) 286-315
275. Peterson L.R., Herrero P., Schechtman K.B., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004) 2191-2196
276. Razeghi P., Young M.E., Alcorn J.L., et al. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
277. Depré C., Shipley G.L., Chen W., et al. Unloaded heart. in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4 (1998) 1269-1275
278. Davila-Roman V.G., Vedala G., Herrero P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 271-277
279. Ataka K., Chen D., Levitsky S., et al. Effect of aging on intracellular Ca2+, pHi, and contractility during ischemia and reperfusion. Circulation 86 (1992) II371-6
280. Lesnefsky E.J., Gallo D.S., Ye J., et al. Aging increases ischemia-reperfusion injury in the isolated, buffer-perfused heart. J Lab Clin Med 124 (1994) 843-851
281. Misare B.D., Krukenkamp I.B., and Levitsky S. Age-dependent sensitivity to unprotected cardiac ischemia. the senescent myocardium. J Thorac Cardiovasc Surg 103 (1992) 60-64
282. Centers for Disease Control. Mortality from coronary heart disease and acute myocardial infarction-United States, 1998. Morbid Mort Weekly Rep 50 (2001) 90-93
283. Abu-Errish G., Neely J.R., Whitmer J., et al. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Physiol 232 (1977) E258-E262
284. McMillin J.B., Taffet G., Taegtmeyer H., et al. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 27 (1993) 2222-2228
285. Escriva F., Agote M., Rubio E., et al. In vivo insulin-dependent glucose uptake of specific tissues is decreased during aging of mature Wistar rats. Endocrinology 138 (1997) 49-54
286. Kates A.M., Herrero P., Dence C., et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 41 (2003) 293-299
287. Soto P.F., Herrero P., Kates A.M., et al. Impact of aging on myocardial metabolic response to dobutamine. Am J Physiol 285 (2003) H2158-H2164
288. Merlet P., Dubois-Rande J.L., Adnot S., et al. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 19 (1992) 10-16
289. Rabinovitch M.A., Rose C.P., Rouleau J.L., et al. Metaiodobenzylguanidine [131I] scintigraphy detects impaired myocardial sympathetic neuronal transport function of canine mechanical-overload heart failure. Circ Res 61 (1987) 797-804
290. Simmons W.W., Freeman M.R., Grima E.A., et al. Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. Circulation 89 (1994) 2843-2851
291. Imamura Y., Ando H., Mitsuoka W., et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 26 (1995) 1594-1599
292. Wakasugi S., Wada A., Hasegawa Y., et al. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 33 (1992) 208-214
293. Takeishi Y., Sukekawa H., Sakurai T., et al. Noninvasive identification of anthracycline cardiotoxicity. comparison of 123I-MIBG and 123I-BMIPP imaging. Ann Nucl Med 8 (1994) 177-182
294. Valdes Olmos R.A., ten Bokkel Huinink W.W., ten Hoeve R.F., et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer 31A (1995) 26-31
295. Merlet P., Valette H., Dubois-Rande J.L., et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 (1992) 471-477
296. Nakata T., Miyamoto K., Doi A., et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 5 (1998) 579-590
297. Ogita H., Shimonagata T., Fukunami M., et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure. a prospective study. Heart 86 (2001) 656-660
298. Wakabayashi T., Nakata T., Hashimoto A., et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 42 (2001) 1757-1767
299. Gerson M.C., McGuire N., and Wagoner L.E. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 9 (2003) 384-391
300. Somsen G.A., van Vlies B., de Milliano P.A., et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 76 (1996) 218-222
301. Takeishi Y., Atsumi H., Fujiwara S., et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38 (1997) 1085-1089
302. Suwa M., Otake Y., Moriguchi A., et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133 (1997) 353-358
303. Kakuchi H., Sasaki T., Ishida Y., et al. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 81 (1999) 148-152
304. Agostini D., Belin A., Amar M.H., et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy. a 123I-MIBG scintigraphic study. J Nucl Med 41 (2000) 845-851
305. Lotze U., Kaepplinger S., Kober A., et al. Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy. assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 42 (2001) 49-54
306. Matsui T., Tsutamoto T., Maeda K., et al. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 66 (2002) 537-543
307. Glowniak J.V., Turner F.E., Gray L.L., et al. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 30 (1989) 1182-1191
308. De Marco T., Dae M., Yuen-Green M.S., et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart. evidence for late reinnervation. J Am Coll Cardiol 25 (1995) 927-931
309. Guertner C., Krause B.J., Klepzig Jr. H., et al. Sympathetic re-innervation after heart transplantation. dual-isotope neurotransmitter scintigraphy, norepinephrine content and histological examination. Eur J Nucl Med 22 (1995) 443-452
310. Estorch M., Camprecios M., Flotats A., et al. Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging. J Nucl Med 40 (1999) 911-916
311. Toba M., Ishida Y., Fukuchi K., et al. Sympathetic reinnervation demonstrated on serial iodine-123-metaiodobenzylguanidine SPECT images after cardiac transplantation. J Nucl Med 39 (1998) 1862-1864
312. Lovric S.S., Avbelj V., Trobec R., et al. Sympathetic reinnervation after heart transplantation, assessed by iodine-123 metaiodobenzylguanidine imaging, and heart rate variability. Eur J Cardiothorac Surg 26 (2004) 736-741
313. Turpeinen A.K., Vanninen E., Kuikka J.T., et al. Demonstration of regional sympathetic denervation of the heart in diabetes. Comparison between patients with NIDDM and IDDM. Diabetes Care 19 (1996) 1083-1090
314. Schnell O., Muhr D., Weiss M., et al. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 45 (1996) 801-805
315. Schnell O., Kirsch C.M., Stemplinger J., et al. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 38 (1995) 1345-1352
316. Schnell O., Muhr D., Dresel S., et al. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up. Diabet Med 14 (1997) 57-62
317. Utsunomiya K., Narabayashi I., Tamura K., et al. Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. Eur J Nucl Med 25 (1998) 1643-1648
318. Utsunomiya K., Narabayashi I., Nakatani Y., et al. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy. Clin Nucl Med 24 (1999) 418-420
319. Kreiner G., Wolzt M., Fasching P., et al. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 44 (1995) 543-549
320. Scognamiglio R., Avogaro A., Casara D., et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31 (1998) 404-412
321. Ohno T., Toyama T., Hoshizaki H., et al. Evaluation of cardiac sympathetic nervous function by 123I-metaiodobenzylguanidine scintigraphy in insulin-treated non-insulin dependent diabetics with hypoglycemia unawareness. Intern Med 35 (1996) 94-99
322. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 (1997) 271-286
323. Nishimura Y., Fukuchi K., Katafuchi T., et al. Superimposed display of coronary artery on gated myocardial perfusion scintigraphy. J Nucl Med 45 (2004) 1444-1449
324. Blankenberg F.G., and Strauss H.W. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 16 (2002) 352-361
325. Sadeghi M.M., Krassilnikova S., Zhang J., et al. Detection of injury-induced vascular remodeling by targeting activated avb3 integrin in vivo. Circulation 110 (2004) 84-90
326. Dobrucki L.W., and Sinusas A.J. Molecular cardiovascular imaging. Curr Cardiol Rep 7 (2005) 130-135
327. Surti S., Karp J.S., Perkins A.E., et al. Imaging performance of A-PET. a small animal PET camera. IEEE Trans Med Imaging 24 (2005) 844-852
328. Schafers K.P., Reader A.J., Kriens M., et al. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med 46 (2005) 996-1004
329. Tai Y.C., Ruangma A., Rowland D., et al. Performance evaluation of the microPET focus. a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46 (2005) 455-463
330. Stegger L., Schafers K.P., Flogel U., et al. Monitoring left ventricular dilation in mice with PET. J Nucl Med 46 (2005) 1516-1521
331. Metzler S.D., Jaszczak R.J., Patil N.H., et al. Molecular imaging of small animals with a triple-head SPECT system using pinhole collimation. IEEE Trans Med Imaging 24 (2005) 853-862
332. Goertzen A.L., Jones D.W., Seidel J., et al. First results from the high-resolution mouseSPECT annular scintillation camera. IEEE Trans Med Imaging 24 (2005) 863-867
333. Beekman F.J., van der Have F., Vastenhouw B., et al. U-SPECT-I. a novel system for submillimeter-resolution tomography with radiolabeled molecules in mice. J Nucl Med 46 (2005) 1194-1200
334. Vanhove C., Lahoutte T., Defrise M., et al. Reproducibility of left ventricular volume and ejection fraction measurements in rat using pinhole gated SPECT. Eur J Nucl Med Mol Imaging 32 (2005) 211-220
335. Constantinesco A., Choquet P., Monassier L., et al. Assessment of left ventricular perfusion, volumes, and motion in mice using pinhole gated SPECT. J Nucl Med 46 (2005) 1005-1011
336. Losordo D.W., Vale P.R., Symes J.F., et al. Gene therapy for myocardial angiogenesis. initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98 (1998) 2800-2804
337. Udelson J.E., Dilsizian V., Laham R.J., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 102 (2000) 1605-1610
338. Hendel R.C., Henry T.D., Rocha-Singh K., et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion. evidence for a dose-dependent effect. Circulation 101 (2000) 118-121
339. Rosengart T.K., Lee L.Y., Patel S.R., et al. Angiogenesis gene therapy. phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100 (1999) 468-474
340. Brooks P., Clark R., and Cheresh D. Requirements of vascular integrin avb3 for angiogenesis. Science 264 (1994) 569-571
341. Meoli D.F., Sadeghi M.M., Krassilnikova S., et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 113 (2004) 1684-1691
342. Hua J., Dobrucki L.W., Sadeghi M.M., et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at avb3 integrin after murine hindlimb ischemia. Circulation 111 (2005) 3255-3260
343. Pfeffer M., and Braunwald E. Experimental observations and clinical implications. ventricular remodeling after myocardial infarction. Circulation 81 (1990) 1161-1172
344. Cohn J., Ferrari R., and Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35 (2000) 569-582
345. Pfeffer M.A., Braunwald E., Moye L.A., et al., The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
346. Sabbah H.N., Sharov V.G., Gupta R.C., et al. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 36 (2000) 1698-1705
347. Spinale F.G. Matrix metalloproteinases. regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
348. Su H., Spinale F.G., Dobrucki L.W., et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112 (2005) 3157-3167
349. Wilson E., Moainie S., Baskin J., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107 (2003) 2857-2863
350. Chen J., Tung C.-H., Allport J., et al. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 111 (2005) 1800-1805
351. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 (1996) 1182-1189
352. Narula J., Acio E.R., Narula N., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 7 (2001) 1347-1352
353. Tuomisto T.T., Binder B.R., and Yla-Herttuala S. Genetics, genomics and proteomics in atherosclerosis research. Ann Med 37 (2005) 323-332
354. Garcia-Touchard A., Henry T.D., Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 25 (2005) 1119-1127
355. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
356. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis. the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
357. LucasAD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Exp Rev Mol Med 2001 5 November, http://www.expertreviews.org/0100369h.htm. Accessed July 5, 2006.
358. Lees A.M., Lees R.S., Schoen F.J., et al. Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins. Arteriosclerosis 8 (1988) 461-470
359. Bozoky Z., Balogh L., Mathe D., et al. Preparation and investigation of 99m technetium-labeled low-density lipoproteins in rabbits with experimentally induced hypercholesterolemia. Eur Biophys J 33 (2004) 140-145
360. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105 (2002) 2708-2711
361. Tawakol A., Migrino R.Q., Hoffmann U., et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12 (2005) 294-301
362. Johnson L.L., Schofield L., Donahay T., et al. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 46 (2005) 1186-1193
363. Kolodgie F.D., Petrov A., Virmani R., et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V. a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108 (2003) 3134-3139
364. Zhou R., Thomas D.H., Qiao H., et al. In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med 46 (2005) 816-822
365. Chin B.B., Nakamoto Y., Bulte J.W., et al. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun 24 (2003) 1149-1154
366. Brenner W., Aicher A., Eckey T., et al. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 45 (2004) 512-518
367. Aicher A., Brenner W., Zuhayra M., et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107 (2003) 2134-2139
368. Kraitchman D.L., Tatsumi M., Gilson W.D., et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112 (2005) 1451-1461
369. Kraitchman D.L., Heldman A.W., Atalar E., et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107 (2003) 2290-2293
370. Benestad H.B., Sundrehagen E., Rolstad B., et al. Migration of 99mTc-labelled syngeneic lymphocytes in the rat. Biological and theoretical models predict radiation damage and poor scintigraphic detectability. J Immunol Methods 135 (1990) 1-8
371. Miyagawa M., Anton M., Haubner R., et al. PET of cardiac transgene expression. comparison of 2 approaches based on herpesviral thymidine kinase reporter gene. J Nucl Med 45 (2004) 1917-1923
372. Wu J.C., Chen I.Y., Wang Y., et al. Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 110 (2004) 685-691
373. Wu J.C., Chen I.Y., Sundaresan G., et al. Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation 108 (2003) 1302-1305
374. Miyagawa M., Beyer M., Wagner B., et al. Cardiac reporter gene imaging using the human sodium/iodide symporter gene. Cardiovasc Res 65 (2005) 195-202
375. Kang J.H., Lee D.S., Paeng J.C., et al. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression. J Nucl Med 46 (2005) 479-483
376. Berman D.S., Kang X., Hayes S.W., et al. Adenosine myocardial perfusion single-photon emission computed tomography in women compared with men. Impact of diabetes mellitus on incremental prognostic value and effect on patient management. J Am Coll Cardiol 41 (2003) 1125-1133